Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06501586Phase 1Completed

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

Role: lead

NCT07324850Phase 1Not Yet Recruiting

A Study of SGB-7342 in Subjects With Obesity or Overweight

Role: lead

NCT06995326Phase 1Not Yet Recruiting

A Study of SGB-3383 in Healthy Subjects

Role: lead

NCT06786338Phase 2Not Yet Recruiting

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

Role: lead

NCT06501573Phase 1Active Not Recruiting

A Study of SGB-9768 in Adult Healthy Volunteers

Role: lead

NCT06239714Phase 1Unknown

A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Role: lead

All 6 trials loaded